Canada & China sign regulatory co-operation agreement
This article was originally published in Clinica
Medical device supervision, adverse event reporting and multilateral co-operation are part of a new 2006 Plan of Action for Regulatory Co-operation between Canada and China. The new agreement builds upon the 1999 Co-operation Workplan and the 2001 Supplementary Agreement.
You may also be interested in...
Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot
Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.